Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Report Guidance | 6 | 1 |
| Clinical Trials by Region | 7 | 8 |
| Clinical Trials and Average Enrollment by Country | 8 | 2 |
| Top Five Countries Contributing to Clinical Trials in Asia-Pacific | 10 | 1 |
| Top Five Countries Contributing to Clinical Trials in Europe | 11 | 1 |
| Top Countries Contributing to Clinical Trials in North America | 12 | 1 |
| Top Five Countries Contributing to Clinical Trials in Middle East and Africa | 13 | 1 |
| Top Five Countries Contributing to Clinical Trials in Central and South America | 14 | 1 |
| Clinical Trials by G7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials | 15 | 1 |
| Clinical Trials by Phase in G7 Countries | 16 | 1 |
| Clinical Trials in G7 Countries by Trial Status | 17 | 1 |
| Clinical Trials by E7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials | 18 | 1 |
| Clinical Trials by Phase in E7 Countries | 19 | 1 |
| Clinical Trials in E7 Countries by Trial Status | 20 | 1 |
| Clinical Trials by Phase | 21 | 2 |
| In Progress Trials by Phase | 22 | 1 |
| Clinical Trials by Trial Status | 23 | 1 |
| Clinical Trials by End Point Status | 24 | 1 |
| Subjects Recruited Over a Period of Time | 25 | 1 |
| Clinical Trials by Sponsor Type | 26 | 1 |
| Prominent Sponsors | 27 | 3 |
| Top Companies Participating in Non-Small Cell Lung Cancer Therapeutics Clinical Trials | 28 | 2 |
| Prominent Drugs | 30 | 1 |
| Latest Clinical Trials News on Non-Small Cell Lung Cancer | 31 | 26 |
| Oct 13, 2016: OncoGenex Announces Results from the Phase 3 ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer | 31 | 1 |
| Oct 12, 2016: Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016 | 31 | 1 |
| Oct 10, 2016: Scancell preparing SCIB2 for clinical study in lung cancer | 32 | 1 |
| Oct 09, 2016: Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer | 33 | 1 |
| Oct 09, 2016: Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Merck s KEYTRUDA (pembrolizumab) for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in a Broad Range of Patients | 34 | 2 |
| Oct 09, 2016: Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advanced Lung Cancer | 36 | 1 |
| Oct 09, 2016: Novartis ALK+ metastatic NSCLC therapy Zykadia extends progression-free survival beyond 18 months in Phase II study | 37 | 1 |
| Oct 09, 2016: Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016 | 38 | 1 |
| Oct 09, 2016: ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumours | 39 | 1 |
| Oct 03, 2016: First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress | 40 | 1 |
| Oct 03, 2016: New Research From Bristol-Myers Squibb at ESMO 2016 Congress Reinforces Leadership in Immuno-Oncology and Differentiated Research Approach | 41 | 3 |
| Sep 29, 2016: Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program | 44 | 1 |
| Sep 28, 2016: Two New Trials of Merck's KEYTRUDA (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016 | 44 | 1 |
| Sep 28, 2016: Merck to Present Phase II Program Updates on Tepotinib at ESMO 2016 | 45 | 1 |
| Sep 28, 2016: Merrimack to Present a Poster on Seribantumab (MM-121) at the European Society for Medical Oncology 2016 Congress | 46 | 1 |
| Sep 26, 2016: Infinity Presents Initial Clinical And New Preclinical Data On IPI-549 At Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference | 46 | 1 |
| Sep 26, 2016: ARMO BioSciences Announces Data Presentations at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference | 47 | 1 |
| Sep 25, 2016: New BGB324 study points to novel mechanism to enhance immunotherapy efficacy | 48 | 1 |
| Sep 23, 2016: Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia in untreated adult ALK+ NSCLC patients | 48 | 1 |
| Sep 21, 2016: Peregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 Congress | 49 | 1 |
| Sep 15, 2016: Zymeworks Doses First Patient in Phase 1 Trial of ZW25, a Novel Bi-Specific Antibody for the Treatment of HER2-Expressing Cancers | 50 | 1 |
| Sep 14, 2016: Heat Biologics Resumes Enrollment in its Non-Small Cell Lung Cancer Trial Evaluating HS-110 in Combination with Anti-PD-1 Checkpoint Inhibitor | 50 | 1 |
| Sep 08, 2016: New analysis showed dose adjustment of Gilotrif (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer | 51 | 1 |
| Aug 31, 2016: Phase III Study Showed Genentech s Cancer Immunotherapy TECENTRIQ (Atezolizumab) Helped People with a Specific Type of Lung Cancer Live Significantly Longer Compared to Chemotherapy | 51 | 1 |
| Aug 29, 2016: Hemispherx Biopharma to Present Data on the Activity of Ampligen Against Cancer at CHI s 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA | 52 | 1 |
| Aug 15, 2016: BeyondSpring Announces First Patient Enrolled in China in a Global Phase 3 Trial of Plinabulin for Non-Small Cell Lung Cancer | 52 | 1 |
| Aug 11, 2016: ValiSeek Clinical Development Update and Regulatory Approval Received for VAL401 in Phase IIB Clinical Trial in Georgia | 53 | 1 |
| Aug 10, 2016: Oncolytics Biotech Reports Additional Data from Randomized Phase II Study of REOLYSIN in Non-Small Cell Lung Cancer | 53 | 1 |
| Aug 09, 2016: Astrazeneca Update on Selumetinib Phase III Trial | 54 | 1 |
| Aug 09, 2016: Influence of Cliical Results from CheckMate-026, a Phase III Study of Opdivo (nivolumab) in Treatment-Na ve Patients with Advanced Non-Small Cell Lung Cancer | 55 | 1 |
| Aug 05, 2016: Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Na ve Patients with Advanced Non-Small Cell Lung Cancer | 55 | 1 |
| Jul 25, 2016: Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA | 56 | 1 |
| Clinical Trial Profile Snapshots | 57 | 3340 |
| Appendix | 3397 | 4 |
| Abbreviations | 3397 | 1 |
| Definitions | 3397 | 1 |
| Research Methodology | 3398 | 1 |
| Secondary Research | 3398 | 1 |
| About GlobalData | 3399 | 1 |
| Contact Us | 3399 | 1 |
| Disclaimer | 3399 | 1 |
| Source | 3400 | 1 |
